Riskpilot← Back to searchSign inGet full accessPHARMA PRODUCTION ApS
APSActiveCVR 66108813Bispensgade 22Accounting, bookkeeping and auditing activities; tax consultancy · NACE 6920Est. 19802 employees
Revenue 2024
DKK 156K
-78% vs 2023
EBITDA margin
83.5%
-80% vs 2023
Equity ratio
65.6%
Financial strength
Net profit 2024
DKK -20K
-105% vs 2023
| Revenue | DKK 156K | -78% |
| EBITDA | DKK 130K | -80% |
| Net profit | DKK -20K | -105% |
| Total assets | DKK 25,2M | -2% |
| Equity | DKK 16,6M | +0% |
| Employees | 2 | — |
Legal name
PHARMA PRODUCTION ApS
CVR number
66108813
Legal form
Anpartsselskab
NACE code
6920 · Accounting, bookkeeping and auditing activities; tax consultancy
Founded
20. juni 1980
Share capital
DKK 400.000
Employees
2 (FTE)
VAT registered
Yes
Audit selected
No
Last report
2024-09-30
Financial year
January – December
Signatory rights
Selskabet tegnes af en direktør.
Company purpose
Selskabets formål er at foretage investering i anlægsaktiver, herunder fast ejendom og værdipapirer, samt hermed efter direktionens skøn beslægtet virksomhed.
Address
Bispensgade 22
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 793 | 1.029 | 964 | 1.072 | 1.168 | 1.084 | 872 | 944 | 837 | 496 | 710 | 695 | 156 |
| Staff expenses | -149 | -64 | -167 | -237 | -257 | -249 | -495 | -516 | -439 | -389 | -469 | -52 | -26 |
| EBITDA | 645 | 965 | 797 | 835 | 911 | 835 | 377 | 428 | 398 | 108 | 241 | 643 | 130 |
| Depreciation & amort. | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 | -0 |
| EBIT | 645 | 965 | 797 | 835 | 911 | 835 | 377 | 428 | 398 | 108 | 241 | 643 | 130 |
| Net financials | -697 | -107 | -694 | -300 | -447 | -18 | -110 | -290 | 6 | 10 | 243 | -151 | -156 |
| Profit before tax | -52 | 858 | 103 | 535 | 464 | 857 | 267 | 137 | 404 | 117 | 484 | 492 | -26 |
| Tax | -13 | 215 | -134 | 48 | -135 | 190 | 59 | 31 | 89 | 26 | 107 | 108 | -6 |
| Net profit | -39 | 644 | 237 | 487 | 599 | 667 | 208 | 106 | 315 | 91 | 377 | 384 | -20 |
| Item | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 26.273 | 26.600 | 27.010 | 26.202 | 26.465 | 26.492 | 26.234 | 25.895 | 25.704 | 25.713 | 25.553 | 25.724 | 25.243 |
| Equity | 12.452 | 13.095 | 13.332 | 13.819 | 14.418 | 15.085 | 15.293 | 15.418 | 15.733 | 15.824 | 16.201 | 16.585 | 16.565 |
| Long-term debt | 7.713 | 7.478 | 7.235 | 6.918 | 6.564 | 6.206 | 5.483 | 5.482 | 10.218 | 4.356 | 3.985 | 3.923 | 3.392 |
| Short-term debt | 2.198 | 2.064 | 2.638 | 1.740 | 1.997 | 1.714 | 1.970 | 1.508 | 1.375 | 2.046 | 1.880 | 1.729 | 1.800 |
| Total debt | 9.912 | 9.542 | 9.874 | 8.659 | 8.561 | 7.920 | 7.453 | 6.990 | 11.593 | 6.401 | 5.865 | 5.652 | 5.191 |
EBITDA margin
83.5%
This company
15.8%
Market median
+428% vs market
20122024
Equity ratio
65.6%
This company
38.2%
Market median
+72% vs market
20122024
Return on equity
-0.1%
This company
18.4%
Market median
-101% vs market
20122024
Net profit margin
-13.1%
This company
8.1%
Market median
-262% vs market
20122024
Asset turnover
0.01×
This company
1.12×
Market median
-99% vs market
20122024
Debt / equity
0.52×
This company
0.62×
Market median
+16% vs market
20122024
- Annual report 2024Filed via CVR / Virk · Period 2023-10-01 – 2024-09-30
- Annual report 2023Filed via CVR / Virk · Period 2022-10-01 – 2023-09-30
- Annual report 2022Filed via CVR / Virk · Period 2021-10-01 – 2022-09-30
- Annual report 2021Filed via CVR / Virk · Period 2020-10-01 – 2021-09-30
- Annual report 2020Filed via CVR / Virk · Period 2019-10-01 – 2020-09-30
- Annual report 2019Filed via CVR / Virk · Period 2018-10-01 – 2019-09-30
- Annual report 2018Filed via CVR / Virk · Period 2017-10-01 – 2018-09-30
- Annual report 2017Filed via CVR / Virk · Period 2016-10-01 – 2017-09-30
- Annual report 2016Filed via CVR / Virk · Period 2015-10-01 – 2016-09-30
- Annual report 2015Filed via CVR / Virk · Period 2014-10-01 – 2015-09-30
- Annual report 2014Filed via CVR / Virk · Period 2013-10-01 – 2014-09-30
- Annual report 2013Filed via CVR / Virk · Period 2012-10-01 – 2013-09-30
- Annual report 2012Filed via CVR / Virk · Period 2011-10-01 – 2012-09-30
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
KS Management | Management | 1980 | — | — |
| Audit | 1980 | — | — |
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
| Board of Directors | 2008 | — | — | |
| Board of Directors | 1980 | — | — | |
| Board of Directors | 2005 | — | — | |
| Board of Directors | 1980 | — | — |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
Bispensgade Holding ApS | Company | 100.0% | 100.0% | 2015 |
| Individual | 100.0% | 100.0% | 1980 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Bispensgade Holding ApS
PHARMA PRODUCTION ApS Board members of PHARMA PRODUCTION ApS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Karen Schou Røhl | Management | 0 companies |
| REVISIONSFIRMAET FINN HARLIS, AALBORG ApS | Audit | 0 companies |
| Henning Anders Julin | Board of Directors | 0 companies |
| Hanne-Mette Marie Johansen Jensen | Board of Directors | 0 companies |
| Hans Christian Hoeck | Board of Directors | 0 companies |
| Freya Selena Petersen | Board of Directors | 0 companies |